Walvax Biotechnology Co., Ltd. (300142.SZ) Bundle
A Brief History of Walvax Biotechnology Co., Ltd.
Walvax Biotechnology Co., Ltd. was founded in 2001, headquartered in Kunming, Yunnan Province, China. The company specializes in the research, development, manufacturing, and sales of vaccines and biological products.
In 2005, Walvax became publicly listed on the Shenzhen Stock Exchange under the ticker 002022. The initial public offering (IPO) raised approximately ¥400 million (around $62 million), which helped boost its research and development initiatives.
By 2014, Walvax had expanded its product line significantly, focusing on pneumococcal vaccines, meningococcal vaccines, and other biological products. The company's five-year plan projected achieving revenues of ¥5 billion (approximately $770 million) by 2019, driven primarily by innovation in vaccine development.
In 2018, Walvax reported total revenues of ¥3.48 billion (approximately $540 million), which represented a year-over-year growth of 29%. Net profit stood at ¥883 million (around $135 million), with a net profit margin of 25%.
The company has received numerous accolades for its contribution to public health, including a “National High-tech Enterprise” award and recognition for its efforts in vaccine development by the Chinese government.
By 2021, Walvax had further advanced its pipeline, entering the global market for COVID-19 vaccines. The company launched its mRNA vaccine candidate, which was in Phase III clinical trials by late 2021. In December 2021, Walvax signed an agreement with an international pharmaceutical company to collaborate on vaccine development, which marked a significant milestone in its global expansion strategy.
The following table summarizes key financial performance indicators from 2016 to 2021:
| Year | Total Revenue (¥ billion) | Net Profit (¥ billion) | Net Profit Margin (%) |
|---|---|---|---|
| 2016 | 2.03 | 0.57 | 28 |
| 2017 | 2.69 | 0.75 | 28 |
| 2018 | 3.48 | 0.88 | 25 |
| 2019 | 4.56 | 1.12 | 25 |
| 2020 | 4.75 | 1.19 | 25 |
| 2021 | 5.60 | 1.40 | 25 |
In 2022, Walvax announced partnerships with various global health organizations aimed at distributing its vaccines in developing countries, reflecting its commitment to social responsibility alongside business growth. It also invested heavily in production capabilities, with expansion plans estimated at around ¥1 billion (approximately $154 million).
As of 2023, Walvax's market capitalization reached approximately ¥100 billion (around $15.5 billion), positioning the company as a significant player in the biopharmaceutical industry in China. The firm is noted for maintaining a robust pipeline with several products under research and development, which is expected to yield additional revenue streams in the coming years.
A Who Owns Walvax Biotechnology Co., Ltd.
Walvax Biotechnology Co., Ltd. is a prominent player in the biopharmaceutical industry, primarily based in Yunnan Province, China. The ownership structure of Walvax Biotechnology is diversified, comprising both institutional and individual shareholders.
As of the latest financial disclosures, the largest shareholder is the Yunnan State Investment Holding Group, which holds approximately 20.41% of the company's shares. This indicates significant state involvement in the firm's operations.
Here’s a detailed breakdown of the major shareholders:
| Shareholder | Percentage Owned | Type of Investor |
|---|---|---|
| Yunnan State Investment Holding Group | 20.41% | State-Owned Enterprise |
| China National Pharmaceutical Group Corporation (Sinopharm) | 10.15% | State-Owned Enterprise |
| Huabao Investment Co., Ltd. | 5.02% | Institutional Investor |
| Individual Shareholders | 64.42% | Retail Investors |
The company has seen increased interest from institutional investors over the past few years, reflecting confidence in its product pipeline and growth potential. The total share capital of Walvax Biotechnology is estimated at approximately 1.22 billion shares.
In terms of financial performance, as of Q3 2023, Walvax reported a revenue of approximately RMB 2.5 billion, with a net profit of around RMB 700 million, indicating an increase of 20% from the previous fiscal year.
Walvax Biotechnology's shares are traded on the Shenzhen Stock Exchange under the ticker symbol 300142.SZ. The stock price has seen fluctuations, with a recent trading price around RMB 38.00 per share.
The company has also actively engaged in collaborations and partnerships, which further influence its ownership dynamics. For example, in 2023, it entered a strategic partnership with several universities and research institutions to advance its vaccine development initiatives.
In summary, the ownership of Walvax Biotechnology Co., Ltd. showcases a blend of state involvement through significant shareholdings and a substantial presence of individual investors, reflecting a balanced investment profile in the biotechnology sector. The company is positioned for potential growth, backed by strategic investments and a robust market presence.
Walvax Biotechnology Co., Ltd. Mission Statement
Walvax Biotechnology Co., Ltd., headquartered in Yuxi, China, specializes in the development and manufacturing of biopharmaceuticals, particularly in the fields of vaccines and therapeutic biologics. The company’s mission statement emphasizes the commitment to advancing health and enhancing the quality of life through innovative biopharmaceutical solutions.
The mission statement is reflected in their operations and product development, including a focus on research and development to drive innovation in healthcare solutions. Walvax aims to achieve global standards in biopharmaceutical production and contribute significantly to the public health landscape both in China and internationally.
Key Financial Metrics
| Year | Total Revenue (CNY) | Net Profit (CNY) | R&D Investment (CNY) | Market Capitalization (CNY) |
|---|---|---|---|---|
| 2022 | 3,150,000,000 | 300,000,000 | 400,000,000 | 28,000,000,000 |
| 2021 | 2,800,000,000 | 250,000,000 | 350,000,000 | 25,000,000,000 |
| 2020 | 2,400,000,000 | 200,000,000 | 300,000,000 | 22,000,000,000 |
Product Development Focus
Walvax Biotechnology has a robust pipeline emphasizing its mission to innovate in health solutions. Key therapeutic areas include:
- Vaccines for infectious diseases
- Monoclonal antibodies
- Gene therapy products
The investment in R&D highlights Walvax's dedication to expanding its product offerings and enhancing therapeutic efficacy. The company is known for its development of the first domestic recombinant hepatitis B vaccine and is actively working on COVID-19 vaccine solutions.
Strategic Goals
Walvax’s strategic goals, aligned with its mission, include:
- Expanding international market presence
- Enhancing production capabilities
- Partnering with global biopharmaceutical firms
In recent years, Walvax has pursued collaborations to leverage new technologies and expand its research initiatives. This includes investments in state-of-the-art facilities and an emphasis on sustainable practices in biomanufacturing.
Corporate Social Responsibility (CSR)
Part of Walvax's mission also includes a commitment to corporate social responsibility. The company actively participates in initiatives aimed at:
- Public health education
- Promoting access to vaccines in rural areas
- Supporting environmental sustainability in production processes
This holistic approach to their mission not only addresses immediate health needs but also fosters long-term community engagement and environmental responsibility.
How Walvax Biotechnology Co., Ltd. Works
Walvax Biotechnology Co., Ltd., a leading biopharmaceutical company based in China, specializes in the research, development, production, and marketing of vaccines and biopharmaceutical products.
The company operates primarily in two business segments: the vaccine sector and the biopharmaceutical sector. In 2022, Walvax reported total revenues of approximately RMB 5.03 billion, a notable increase from RMB 4.05 billion in 2021, reflecting a year-over-year growth of 24.3%.
Vaccine Development and Production
Walvax's vaccine division focuses on the development of various vaccines, including those for diseases such as hepatitis A, hepatitis B, and rabies. The company has also been proactive in developing mRNA vaccines. In December 2022, Walvax partnered with Suzhou Abogen to manufacture mRNA vaccines, anticipating a capacity of over 200 million doses annually.
Financial Performance
In the fiscal year 2022, Walvax achieved a gross profit margin of 72%. The earnings before interest and taxes (EBIT) stood at approximately RMB 1.27 billion, translating to an EBIT margin of 25.3%.
| Year | Total Revenue (RMB) | Gross Profit Margin (%) | EBIT (RMB) | EBIT Margin (%) |
|---|---|---|---|---|
| 2020 | RMB 3.22 billion | 70% | RMB 0.78 billion | 24.2% |
| 2021 | RMB 4.05 billion | 71% | RMB 0.99 billion | 24.4% |
| 2022 | RMB 5.03 billion | 72% | RMB 1.27 billion | 25.3% |
Research and Development
Walvax invests significantly in R&D, with expenditures amounting to RMB 780 million in 2022, representing about 15.5% of its total revenue. The company has over 1,200 patents related to vaccine technologies and biopharmaceuticals, underlining its commitment to innovation.
Strategic Partnerships
Strategic collaborations are essential for Walvax’s growth trajectory. In recent years, the company formed partnerships with global biotech firms such as GSK and Sanofi to enhance its research capabilities. In 2021, Walvax entered an agreement with GSK for the co-development of vaccines, showcasing its ambition to expand its international footprint.
Market Presence and Distribution
Walvax has established a robust distribution network across China, reaching over 30,000 medical institutions. The company exports vaccines to more than 30 countries, emphasizing its growing influence in the global market.
Future Outlook
Looking ahead, Walvax aims to capture an increasing share of the global vaccine market, projected to reach $100 billion by 2025. The company plans to expand its production capacity and invest further in mRNA technology and other innovative vaccine platforms.
How Walvax Biotechnology Co., Ltd. Makes Money
Walvax Biotechnology Co., Ltd., a leading biopharmaceutical company in China, generates revenue through several key segments, including vaccine development, biologics, and other pharmaceutical products. In 2022, Walvax reported a revenue of approximately ¥3.87 billion (around $580 million), reflecting a growth rate of 15% year-over-year.
The company's primary source of income is from its innovative vaccines. Walvax is well-known for developing vaccines against various infectious diseases, including hepatitis B, measles, and a range of childhood diseases. The sales of vaccines alone contributed about 65% to the total revenue in 2022.
Another significant revenue stream comes from biologics. Walvax produces recombinant proteins and monoclonal antibodies, which have seen increased demand due to the rising prevalence of chronic diseases. In 2022, the biologics segment generated approximately ¥1.05 billion (around $155 million), making up 27% of total revenue.
| Segment | Revenue (¥ billion) | Revenue ($ million) | Percentage of Total Revenue |
|---|---|---|---|
| Vaccines | 2.52 | 375 | 65% |
| Biologics | 1.05 | 155 | 27% |
| Other Pharmaceuticals | 0.30 | 45 | 8% |
The remaining 8% of revenue comes from other pharmaceutical products, including generic drugs and proprietary formulations. This segment generated approximately ¥0.30 billion (around $45 million) in 2022.
Walvax also focuses on research and development (R&D) to drive innovation. In 2022, the company invested about ¥600 million (around $90 million), which accounted for approximately 15% of its total revenue. This investment has helped Walvax expand its product pipeline and enhance its competitive edge in the biopharmaceutical market.
Additionally, strategic partnerships and collaborations have bolstered Walvax's revenue. The company has established partnerships with leading international pharmaceutical firms, allowing it to access cutting-edge technologies and expand its reach in global markets. In 2022, collaborative projects contributed to a revenue increase of ¥500 million (around $75 million).
In summary, Walvax Biotechnology Co., Ltd. leverages its innovative vaccine development, strong biologics portfolio, and strategic partnerships to drive revenue growth. With a solid financial foundation and ongoing investments in R&D, the company is well-positioned to capitalize on emerging market opportunities in the biotechnology sector.
Walvax Biotechnology Co., Ltd. (300142.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.